WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that
it has named Paolo Baroldi, M.D.,
Ph.D. as its Senior Vice President and Chief Medical Officer.
Dr. Baroldi has over 30 years of clinical development experience
in many therapeutic areas, including neurology and
psychiatry. He has been working in the role of acting
Chief Medical Officer with Vanda since October 1, 2012.
"We welcome Paolo to Vanda and look forward to his leadership in
strengthening our clinical organization," said Mihael H. Polymeropoulos, M.D., President and
Chief Executive Officer of Vanda.
Dr. Baroldi previously served as the Senior Vice President and
Chief Medical Officer of Vanda from July
2006 through January 2009. He has served in senior
clinical development positions at Galileo Research, Supernus
Pharmaceuticals, Chiesi Farmaceutici SpA, and Novartis AG.
Dr. Baroldi holds M.D. and Ph.D. degrees from the University of
Milan, Italy and is a member of
the board of directors of Galileo Research.
ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company
focused on the development and commercialization of products for
the treatment of central nervous system disorders. For more
on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com.
Company Contact
Jim Kelly
Senior Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
SOURCE Vanda Pharmaceuticals Inc.